Leveraging large language models to improve patient education on dry eye disease.

Background/objectives: Dry eye disease (DED) is an exceedingly common diagnosis in patients, yet recent analyses have demonstrated patient education materials (PEMs) on DED to be of low quality and readability. Our study evaluated the utility and performance of three large language models (LLMs) in enhancing and generating new patient education materials (PEMs) on dry eye disease (DED).

Subjects/methods: We evaluated PEMs generated by ChatGPT-3.

[Anticipated prescription of X-ray from triage. State of the art in minor limb trauma].

Minor traumatology is a common reason for consultation in the emergency room and requires a radiographic assessment in most cases. To improve patient comfort, reduce the feeling of waiting and decrease the length of stay, actions entrusted to the triage nurse (TN) have been developed, such as the anticipated prescription of X-ray (APXray). In Switzerland, this practice seems to be heterogeneous and lacks any established legal framework, prescribing being an exclusively medical act.

Utility of pan-bacterial and pan-fungal PCR in endophthalmitis: case report and review of the literature.

Background: Endophthalmitis is a clinical diagnosis but identification of the disease-causing agent or agents allows for a more tailored treatment. This is routinely done through intraocular fluid cultures and staining. However, culture-negative endophthalmitis is a relatively common occurrence, and a causative organism cannot be identified.

Translation of HDAC6 PET Imaging Using [F]EKZ-001-cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates.

Histone deacetylase 6 (HDAC6) is a multifunctional cytoplasmic enzyme involved in diverse cellular processes such as intracellular transport and protein quality control. Inhibition of HDAC6 can alleviate defects in cell and rodent models of certain diseases, particularly neurodegenerative disorders, including Alzheimer's disease and amyotrophic lateral sclerosis. However, while HDAC6 represents a potentially powerful therapeutic target, development of effective brain-penetrant HDAC6 inhibitors remains challenging.